Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11309017 | 0.84 | RHOA (0.54) | NEK2CDK2ROCK1SYKAURKA | |
| SCHEMBL4649803 | 0.82 | CAMK2D (0.45) | CDK2SYK | |
| SCHEMBL4920877 | 0.79 | NEK2 (0.53) | NEK2CDK2SYKCDK19ALK | |
| SCHEMBL4919662 | 0.78 | NEK2 (0.48) | NEK2CDK2SYKAURKACDK19 | |
| SCHEMBL8539781 | 0.78 | MAPK1 (0.50) | NEK2CDK2SYKAURKA | |
| SCHEMBL4649832 | 0.77 | PTK2 (0.50) | NEK2 | |
| SCHEMBL4650371 | 0.75 | PTGS1 (0.43) | — | |
| SCHEMBL10171951 | 0.74 | IRAK4 (0.63) | — | |
| SCHEMBL19691014 | 0.73 | POLB (0.44) | — | |
| SCHEMBL2464073 | 0.73 | SCN9A (0.55) | ROCK1SYKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | NEK2 609/4885CDK2 252/4885ROCK1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.